Baricitinib Achieved Complete or Near Complete Scalp Coverage in SALT Score ≤20 Responders: 52-Week Findings From BRAVE-AA Trials

The BRAVE-AA trials demonstrated that baricitinib is effective in treating severe alopecia areata, with a focus on patients achieving a SALT score ≤20. Over 52 weeks, 75% of patients on a 4-mg dose and 71% on a 2-mg dose achieved a SALT score ≤10, indicating significant hair regrowth. Additionally, 62.7% of the 4-mg group and 47.3% of the 2-mg group reached a SALT score ≤5. Patients with less severe baseline disease showed better responses, with improvements noticeable as early as week 8 and increasing with continued treatment.